← All stocks

Akebia Therapeutics, Inc.

AKBA No buying or selling
CIK 0001517022 #3754 in the set updated 19 Sep 2026
Bought (1 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (1 mo)
$0.00
$0.00 on a plan · $0.00 straight out of an exercise
Sold at will
$0.00
0 of 0 sales
Net
$0.00
$0.00 against sales at will

By person

13 insiders · 0 transactions
4.7×

John P. Butler holds only 4.7 times base salary in stock. $4.13M of shares against $864.01K in salary for 2025.

Salary from the company's own proxy. The shares are what John P. Butler last reported holding, valued at $1.11, the price Common Stock was last bought or sold at on the open market here, on 29 Jun 2026.

Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Butler John P.
CEO and President
3,718,564
$4.13M
+68.1%
Burke Steven Keith
SVP, Chief Medical Officer
948,432
$1.05M
+40.5%
Ostrowski Erik
SVP, CFO, CBO & Treasurer
616,616
$684.44K
+76.2%
Rucci Carolyn M.
SVP, Chief Legal Officer
588,378
$653.10K
+25.7%
Grund Nicholas
Chief Commercial Officer
561,750
$623.54K
+85.2%
Malabre Richard C
SVP, Chief Accounting Officer
299,390
$332.32K
+31.1%
ADAMS ADRIAN
Director
236,200
$262.18K
+43.3%
ROGERS MICHAEL W
Director
197,429
$219.15K
+56.7%
Smith Cynthia
Director
196,633
$218.26K
+57.0%
Wolf Myles
Director
169,081
$187.68K
+73.1%
FRIESON RON
Director
165,200
$183.37K
+124.2%
GILMAN STEVEN C
Director
152,830
$169.64K
+30.5%
ZUMWALT LEANNE M
Director
145,100
$161.06K
+96.9%

No percentages here. These insiders hold more than one class of share between them, and the share count on file covers one of them rather than all. Dividing the two would compare different things.

Nothing of that kind in this period.

What was left out

Form 4 filings counted 0
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 0
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 0
History held since 4 Oct 2016